Book-runners are Piper Jaffray and Cantor Fitzgerald.
Underwriters will get a 30-day optino to buy up to an additional 15% of shares.
Proceeds will be used for the commercialization of Dialysate Triferic and I.V. Triferic, as well as research and development and general purposes.
Subscribe for full text news in your inbox